GSA Capital Partners LLP Buys New Stake in NeuroPace, Inc. $NPCE

GSA Capital Partners LLP bought a new stake in shares of NeuroPace, Inc. (NASDAQ:NPCE) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 115,535 shares of the company’s stock, valued at approximately $1,836,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Legal & General Group Plc increased its holdings in shares of NeuroPace by 86.0% during the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock valued at $30,000 after purchasing an additional 1,239 shares during the period. Quantbot Technologies LP bought a new stake in shares of NeuroPace during the second quarter valued at about $35,000. Quarry LP lifted its holdings in NeuroPace by 94.9% in the third quarter. Quarry LP now owns 3,845 shares of the company’s stock worth $40,000 after purchasing an additional 1,872 shares during the period. New York State Common Retirement Fund lifted its holdings in NeuroPace by 755.6% in the fourth quarter. New York State Common Retirement Fund now owns 7,700 shares of the company’s stock worth $119,000 after purchasing an additional 6,800 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in NeuroPace by 60.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,160 shares of the company’s stock worth $147,000 after purchasing an additional 4,972 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on NPCE shares. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of NeuroPace in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a research note on Wednesday, June 24th. Mizuho began coverage on shares of NeuroPace in a report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price objective for the company. Finally, Guggenheim reiterated a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.29.

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $14.77 on Monday. NeuroPace, Inc. has a twelve month low of $8.17 and a twelve month high of $19.60. The company has a current ratio of 4.94, a quick ratio of 3.91 and a debt-to-equity ratio of 4.97. The firm has a 50-day moving average of $15.48 and a two-hundred day moving average of $15.36. The company has a market capitalization of $506.91 million, a price-to-earnings ratio of -25.91 and a beta of 1.92.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. The business had revenue of $22.83 million during the quarter, compared to analyst estimates of $22.61 million. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. As a group, analysts expect that NeuroPace, Inc. will post -0.54 earnings per share for the current fiscal year.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.